Studies on the stability of injectable L-ascorbic acid solutions. II. Effect of metal ions and oxygen content of solvent water.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M A Kassem.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The pharmacokinetics of mofebutazone was investigated in man after oral administration of [4-14C] mofebutazone in suspension form (7 mg/kg body weight). The blood concentration/time course was found to fit a two compartment open model with first order absorption (ka = 10.1 h-1) where elimination (kel = 0.304 h-1) occurs only from compartment 1. The maximum concentration was reached after 0.3 h in compartment 1 and after 2 h in compartment 2. Mofebutazone was found to be excreted almost exclusively via the kidney; 97% of the administered dose was found in urine already at 72 h. Excretion takes place very rapidly; 24% of the dose was excreted in 1.5 h and 45% in 3 h. 92% of the mofebutazone excreted was the conjugated form. Two glucuronides were detected in the 24 h urine; one of these seemed to be identical to a glucuronide fractionated from the urine of rat. The renal clearance of mofebutazone in man was found to be 3.38 l/h. The almost complete recovery of mofebutazone in the urine indicates that after oral administration, this drug has a very high bioavailability via the oral route.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.